Trial reportKidney & blood pressure research2012
Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial.
Trial report in Kidney & blood pressure research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 16 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 16 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes.Annals of medicine · 2025Pooled it
- Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.PloS one · 2025Pooled it
- Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.BMC nephrology · 2024Pooled it
- Non-immunosuppressive treatment for IgA nephropathy.The Cochrane database of systematic reviews · 2024Pooled it
- Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies.Renal failure · 2022Pooled it
- Hyperuricemia aggravates the progression of IgA nephropathy.International urology and nephrology · 2022Pooled it
- Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.Frontiers in pharmacology · 2022Pooled it
- Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.Clinical rheumatology · 2020Pooled it
- Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.Renal failure · 2018Pooled it
- Pooled it
- Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.International journal of molecular sciences · 2017Pooled it
- Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2017Pooled it
- Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis.PloS one · 2017Pooled it
- Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.BMC nephrology · 2015Pooled it
- Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.Pediatric nephrology (Berlin, Germany) · 2021Trial
- Pharmacological interventions in IgA nephropathy: protocol for a living systematic review and network meta-analysis.BMJ open · 2025Article
- Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics.Cell death discovery · 2024Review
- Insights into the relationship between serum uric acid and pulmonary hypertension (Review).Molecular medicine reports · 2024Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundHyperuricemia is an independent risk factor for renal progression in IgA nephropathy (IgAN). However, no study has evaluated the effect of allopurinol on the clinical outcome in hyperuricemic IgAN.
methodsFirst,a retrospective cohort study of 353 IgAN patients was conducted to explore the relationship between uric acid (UA) and the progression of renal disease over a mean period of 5 years. Then, 40 hyperuricemic IgAN patients were randomized to receive allopurinol (100-300 mg/day) or usual therapy for 6 months. The study outcomes were renal disease progression and/or blood pressure.
resultsHyperuricemia independently predicted renal survival at 1, 3, and 5 years after adjustment for different baseline estimated glomerular filtration rates. In the randomized controlled trial, allopurinol did not significantly alter renal progression or proteinuria. The antihypertensive drug dosage was reduced in 7 of 9 cases with hypertension in the allopurinol group compared to 0 of 9 cases in the control group (p < 0.01). UA levels correlated with mean arterial pressure in normotensive patients (r = 0.388, p < 0.001).
conclusionHyperuricemia predicts the progression of IgAN independently of baseline estimated glomerular filtration rate. Allopurinol may improve the control of blood pressure. Further studies are required to explore the effects of lowering UA on renal protection in IgAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.